Description

TELMAHEAL 80 MG

Indications

TELMAHEAL 80 MG is primarily indicated for the management of essential hypertension in adults. It is often prescribed to help lower blood pressure, thereby reducing the risk of cardiovascular events such as stroke and heart attack. Additionally, TELMAHEAL may be used in patients with certain kidney disorders, particularly in those with type 2 diabetes, to protect renal function.

Mechanism of Action

TELMAHEAL contains Telmisartan, an angiotensin II receptor blocker (ARB). It works by selectively blocking the binding of angiotensin II to the AT1 receptor, which is responsible for the vasoconstrictive effects of angiotensin II. By inhibiting this receptor, Telmisartan causes vasodilation, leading to a decrease in blood pressure. Furthermore, it helps to reduce the secretion of aldosterone, which in turn decreases sodium and water retention, contributing to lower blood volume and blood pressure.

Pharmacological Properties

Telmisartan is well-absorbed after oral administration, with peak plasma concentrations occurring within 0.5 to 1 hour. The bioavailability of Telmisartan is approximately 50%, and it is highly protein-bound (approximately 99.5%). The elimination half-life is around 24 hours, allowing for once-daily dosing. Telmisartan is metabolized primarily in the liver and excreted mainly via feces, with a small percentage eliminated through urine. Its pharmacokinetic profile supports its efficacy in managing hypertension over a 24-hour period.

Contraindications

TELMAHEAL is contraindicated in patients with a known hypersensitivity to Telmisartan or any of its excipients. It should not be used during pregnancy, especially in the second and third trimesters, due to the risk of fetal harm. Additionally, it is contraindicated in patients with severe hepatic impairment, biliary obstruction, or severe renal impairment without dialysis. Caution is advised in patients with conditions that may lead to hyperkalemia.

Side Effects

Common side effects associated with TELMAHEAL include dizziness, fatigue, headache, and abdominal pain. Some patients may experience hypotension, particularly after the first dose, and renal impairment may occur in susceptible individuals. Rare but serious side effects can include angioedema, liver function abnormalities, and hyperkalemia. Patients should be monitored for these adverse effects, especially when initiating therapy or adjusting the dosage.

Dosage and Administration

The recommended starting dose of TELMAHEAL for adults is 40 mg once daily. Depending on the patient’s response and blood pressure levels, the dosage may be increased to a maximum of 80 mg once daily. It is important to take TELMAHEAL at the same time each day, with or without food, to maintain consistent blood levels. For patients with renal impairment, dose adjustments may be necessary, and it is advisable to consult a healthcare provider for individual recommendations.

Interactions

TELMAHEAL may interact with other medications, potentially altering its effectiveness or increasing the risk of adverse effects. Co-administration with potassium-sparing diuretics, potassium supplements, or other agents that increase potassium levels can lead to hyperkalemia. Non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the antihypertensive effect of Telmisartan and increase the risk of renal impairment. Therefore, it is essential to inform healthcare providers about all medications being taken, including over-the-counter drugs and supplements.

Precautions

Prior to initiating therapy with TELMAHEAL, a thorough medical history and assessment of renal function should be conducted. Patients with a history of renal artery stenosis, heart failure, or those who are volume-depleted should be monitored closely. Blood pressure should be regularly monitored to assess the effectiveness of the treatment and to detect any potential hypotension. Patients should also be advised to maintain adequate hydration and to avoid abrupt discontinuation of the medication, as this may lead to rebound hypertension.

Clinical Studies

Clinical studies have demonstrated the efficacy of TELMAHEAL in reducing blood pressure in patients with essential hypertension. In a randomized, double-blind, placebo-controlled trial, patients receiving Telmisartan showed a significant reduction in both systolic and diastolic blood pressure compared to those receiving placebo. Furthermore, long-term studies have indicated that Telmisartan not only lowers blood pressure but also provides renal protective effects in patients with type 2 diabetes, thereby reducing the progression of diabetic nephropathy.

Conclusion

TELMAHEAL 80 MG is an effective antihypertensive medication that plays a crucial role in managing high blood pressure and protecting renal function in certain patient populations. Its mechanism of action as an angiotensin II receptor blocker, combined with its favorable pharmacokinetic profile, makes it a valuable option for healthcare providers. However, as with all medications, it is essential to use TELMAHEAL responsibly and under the guidance of a healthcare professional to minimize risks and maximize therapeutic benefits.